A new study, recently published in the European Journal of Preventive Cardiology, suggests that exposure to blue light may help reduce high blood pressure.
For the study, a team of researchers assessed whether blue light exposure could produce enough nitric oxide to significantly reduce high blood pressure. They involved 14 male participants aged between 30 and 60 years without a previous diagnosis of cardiovascular conditions.
The authors of the study come into a conclusion: “Our present study demonstrates for the first time that whole-body blue light exposure at doses that are comparable to daily sunlight exposure decreases systolic blood pressure […] in young, healthy male volunteers.”
A new Danish research finds that one of the most popular blood pressure drug used around the globe to treat hypertension can increase the risk of developing skin cancer by seven times.
A team of scientists, led by Anton Pottegard, associate professor of clinical pharmacology at the University of Southern Denmark in Odense, examined the association between the common drug hydrochlorothiazide (HCTZ) and the risk of non-melanoma skin cancer.
Having analyzed the data of over 80,000 patients, the researchers found that those who took HTCS had 7 times higher chances to develop skin cancer.
Anton Pottergard comments: “We knew that hydrochlorothiazide made the skin more vulnerable to damage from the sun’s UV rays, but what is new and also surprising is that long-term use of this blood pressure medicine leads to such significant increase in the risk of skin cancer.”
MediGoo is attending the largest health/medical industry event in Düsseford, Germany. We welcome you to visit our stand at hall 15 booth E55. Welcome, hope to see you there 15E55.